CD34 and myelodysplastic syndrome: To address this uncertainty, we investigated the relative impact of CD34+ and CD3+ cell doses on outcomes of myeloablative conditioning (MAC) 10/10 HLA-matched PBSC HCT in patients with myelodysplastic neoplasm (MDS)/AML or AML in first morphologic remission with and without detectable MRD in pre-HCT bone marrow specimens.